European Health Union: Commission establishes portfolio of 10 most promising treatments for COVID-19
Delivering on a key action from the EU Strategy on COVID-19 Therapeutics, the Commission is establishing a portfolio of 10 potential COVID-19 therapeutics. The list established is based on independent scientific advice, and focuses on COVID-19 treatment candidates that are likely to be authorised and therefore available on the European market soon. These therapeutics will bring treatment to patients across the EU as fast as possible provided that their safety and effectiveness has been confirmed by the European Medicines Agency.
Vaccination against COVID-19 offers the best preventive protection against infection, severe disease, loss of life and long-term consequences of illness. While vaccination offers the best way to end the pandemic and get back to normal life, in parallel, we are ensuring that the COVID-19 therapeutics are available to treat those who are infected.
Vice-President for Promoting our European Way of Life, Margaritis Schinas recently said:
“As we continue to face the challenge of COVID-19, it is important to shield ourselves in addition to vaccination. The establishment of 10 COVID-19 therapeutics will ensure that citizens receive the most promising treatments against the virus.”
Commissioner for Health and Food Safety, Stella Kyriakides, recently said:
“Vaccination is the only tool to prevent COVID hospitalisations and deaths, and as such, it is the only way out of this pandemic. In the meantime however, COVID-19 patients do need safe and effective treatments to fight the infection, improve their prospect of a swift recovery, reduce hospitalisations and most importantly, to prevent loss of life. We have already signed four joint procurement contracts for different COVID-19 treatments and we stand ready to negotiate more. Our goal is to authorise at least three therapeutics in the coming weeks and possibly two more by the end of the year and help Member States gain access to them as soon as possible.”
The EU Strategy on COVID-19 Therapeutics is an integral element of the work to build a strong European Health Union, and is modelled on the successful EU Vaccines Strategy.
A group of independent scientific experts has screened 82 therapeutic candidates in late stage clinical development and identified 10 candidates as the most promising for the EU portfolio of COVID-19 treatments, taking into account that different types of products are needed for different patient populations and at different stages and severity of the disease. The list of ten is divided in three categories of treatments and will continue to evolve as new scientific evidence emerges:
- Antiviral monoclonal antibodies that are most efficacious in the earliest stages of infection:
- Ronapreve, a combination of two monocolonal antibodies casirivimab and imdevimab from Regeneron Pharmaceuticals and Roche.
- Xevudy (sotrovimab) from Vir Biotechnology and GlaxoSmithKline.
- Evusheld, a combination of two monoclonal antibodies tixagevimab and cilgavimab from AstraZeneca.
- Oral antivirals for use as quickly as possible after the infection:
- Molnupiravir from Ridgeback Biotherapeutics and MSD.
- PF-07321332 from Pfizer.
- AT-527 from Atea Pharmaceuticals and Roche.
- Immunomodulators to treat hospitalised patients:
- Actemra (tocilizumab) from Roche Holding.
- Kineret (anakinra) from Swedish Orphan Biovitrum.
- Olumiant (baricitinib) from Eli Lilly.
- Lenzimulab from Humaningen.
Latest News from
Commission welcomes the political agreement on the European Year of Youth08/12/2021 09:25:00
The Commission welcomes the political agreement reached yesterday evening by the European Parliament and the Council to make 2022 the European Year of Youth.
EU to designate 2022 as the European Year of Youth07/12/2021 16:33:00
The Council and the European Parliament wish to honour young people by making 2022 the European Year of Youth.
Council agrees on common position to tackle gender pay gap07/12/2021 15:25:00
The Council yesterday agreed on its position on a draft law on pay transparency which will help to tackle the existing pay discrimination at work and contribute to closing the gender pay gap.
Council agrees on mandate for negotiations on a EU framework on adequate minimum wages07/12/2021 14:33:00
The Council yesterday agreed its position on a Commission proposal for an EU law on adequate minimum wages in the EU.
EU Global Human Rights Sanctions Regime - annual review of annex07/12/2021 13:25:00
The Council yesterday adopted a decision prolonging the sanctions against individuals and entities responsible for serious human rights violations and abuses in various countries worldwide for one year, until 8 December 2022.
Eurobarometer: Europeans show support for digital principles07/12/2021 12:38:00
According to a special Eurobarometer survey conducted in September and October 2021, an overwhelming majority of EU citizens think that the Internet and digital tools will play an important role in the future.
Brexit Adjustment Reserve: Commission approves €920.4 million pre-financing for Ireland07/12/2021 11:33:00
The European Commission has adopted the decision to allocate funding from the Brexit Adjustment Reserve to Ireland, for a total of €920.4 million.
Germany: CHANCEN eG receives European support for providing student financing03/12/2021 11:33:00
The European Investment Fund (EIF) has signed a guarantee agreement with CHANCEN eG covering a portfolio of up to €30 million of income sharing agreements (ISAs) to support students in Germany wishing to invest in their studies and upgrade their skills.
Anti-money laundering: Council agrees its negotiating mandate on transparency of crypto-asset transfers03/12/2021 10:38:00
EU ambassadors recently (01 December 2021) agreed on a mandate to negotiate with the European Parliament on a proposal to update existing rules on information accompanying transfers of funds.